开发用于癌症治疗的体内 CAR T 细胞疗法的进展和挑战。
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.
机构信息
School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia; Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia; School of Clinical Medicine, Faculty of Medicine, University of New South Wales Sydney, Kensington, NSW 2052, Australia.
School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
出版信息
EBioMedicine. 2024 Aug;106:105266. doi: 10.1016/j.ebiom.2024.105266. Epub 2024 Aug 1.
The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ. This review offers a comprehensive overview of recent advancements in the development of T cell-targeted CAR generation in situ. Additionally, it identifies the challenges associated with in vivo CAR T method and potential strategies to overcome these issues.
嵌合抗原受体 (CAR) T 细胞疗法已成为癌症治疗中一种突破性的免疫治疗方法。为了克服当前体外 CAR T 细胞疗法产品的复杂性和高制造成本，近年来已经开发出了在体内直接产生 CAR T 细胞的替代策略。这些策略涉及通过工程化的纳米载体或病毒载体直接输注 CAR 基因，以在体内原位产生 CAR T 细胞。本综述全面介绍了体内 CAR T 方法的最新进展，并确定了与体内 CAR T 方法相关的挑战和潜在的克服这些问题的策略。
Zotero 插件